Finance

Roʻyxatlar
4559:TYO
Zeria Pharmaceutical Co Ltd
1 898,00 JP¥
0,00%
(0,00) 1K
2-okt, 15:30:00 (GMT+9)  ·   JPY
Barcha belgilar
BelgiNarxiOʻzgartirishlarDinamika (%)
4559 tikeri uchun statistika yaratilmoqda...
Bozor kapitali
95,13 mlrd
Oʻrtacha hajm
167,72 ming
Hajmi
0,00
Dividend
2,58%
Choraklik dividendlar
12 JP¥
Eks-dividend sanasi
29-sen, 2026
P/E koeffitsiyenti
10,17
52 haftalik eng yuqori
2 434 JP¥
52 haftalik eng past
1 878 JP¥
Aksiya boʻyicha daromad
187 JP¥
Muomaladagi aksiyalar
50,11 mln
Xodimlar soni
2 ming
Bozor kapitali
95,13 mlrd
Oʻrtacha hajm
167,72 ming
Hajmi
0,00
Dividend
2,58%
Choraklik dividendlar
12 JP¥
Eks-dividend sanasi
29-sen, 2026
P/E koeffitsiyenti
10,17
52 haftalik eng yuqori
2 434 JP¥
52 haftalik eng past
1 878 JP¥
Aksiya boʻyicha daromad
187 JP¥
Muomaladagi aksiyalar
50,11 mln
Xodimlar soni
2 ming
Yangiliklar
Internet manbalari va yangilik hamkorlarimizdan
Profil
Zeria Shinyaku Kōgyō KK is a Japanese drug manufacturer that obtained Tillotts Pharma AG. In 1955, the Japanese Kisaku Ibu, former Yamanouchi Seiyaku executive opened a new pharmaceutical company in Tokyo under the name Zeria Yakushō Kenkyusho. In 1970, this company becomes Zeria Shinyaku Zeria Shinyaku KK. In 1975, it built a new factory in Kumagaya in Saitama prefecture, before the main factory in Tsukuba which was constructed by Takenaka Corporation in 1988. In 2009, the company obtained Switzerland company Tillotts Pharma AG, and began operating internationally through a large network of subsidiaries, It manufactures and sells pharmaceuticals in Sweden, Ireland, UK, Czech Republic, Spain, Germany, France, Italy, Vietnam and Denmark. The drug itself is developed in Switzerland, Tillotts Parma. The company owns a 6.63% share of Asuka Seiyaku, also a pharmaceutical company, other than its subsidiaries. The main shareholder of the company is the company itself, the present president Mitsuhiro Ibu, Mitsubishi UFJ Financial Group, Custody Bank of Japan, Morinaga Milk Industry, SMBC, Mizuho Bank, Risona Bank, Aioi Nissay Dowa Insurance as of March 2023. Wikipedia
Zeria Pharmaceutical Co Ltd haqida
CEOSachiaki Ibe
Xodimlar soni1,75 ming
Asos solingan22-dek, 1955
Bosh ofislar-
Sektor-
Veb-saytzeria.co.jp
Avvalgi hisobotlarBarcha qiymatlar – JPY
Loading Previous Earnings...
Daromad
Sof foyda
Barcha qiymatlar – JPY
sen, 2025
dek, 2025
mar, 2026
iyn, 2026
Daromad
20,47 mlrd
24,12 mlrd
25,08 mlrd
21,45 mlrd
Sotilgan mahsulotning tannarxi
5,59 mlrd
6,38 mlrd
6,43 mlrd
6,22 mlrd
Daromad narxi
5,59 mlrd
6,38 mlrd
6,43 mlrd
6,22 mlrd
Tadqiqot va ishlanmalarga xarajatlar
-
-
3,71 mlrd
-
Tadqiqot va ishlanmalarga xarajatlar jami xarajatlar
-
-
-
-
Tijoriy, umumiy va maʼmuriy xarajatlar
12,76 mlrd
12,82 mlrd
4,85 mlrd
13,28 mlrd
Operatsion xarajatlar
12,76 mlrd
12,82 mlrd
14,84 mlrd
13,28 mlrd
Jami operatsion xarajatlar
18,35 mlrd
19,19 mlrd
21,27 mlrd
19,50 mlrd
Operatsion daromad
2,12 mlrd
4,93 mlrd
3,81 mlrd
1,95 mlrd
Boshqa nooperatsion daromad
-23,00 mln
-81,04 mln
305,04 mln
-47,28 mln
Soliq toʻlangunga qadar foyda, shu jumladan gʻayrioddiy moddalar
994,00 mln
4,63 mlrd
3,92 mlrd
1,43 mlrd
Soliq toʻlangunga qadar foyda, gʻayrioddiy moddalar bundan mustasno
994,00 mln
4,63 mlrd
3,76 mlrd
1,43 mlrd
Daromad soligʻi boʻyicha xarajat
383,00 mln
795,44 mln
979,56 mln
547,57 mln
Amaldagi soliq stavkasi
38,53%
-
25,02%
38,21%
Boshqa operatsion xarajatlar
-
-
-
-
Sof foyda
647,00 mln
3,82 mlrd
2,90 mlrd
866,20 mln
Sof foyda marjasi
3,16%
-
11,56%
4,04%
Har bir aksiya foydasi
-
-
-
-
Foizlar va investitsiyalardan olingan daromadlar
30,00 mln
136,71 mln
32,29 mln
305,03 mln
Foizlarni toʻlash xarajatlari
-119,00 mln
-123,00 mln
-138,00 mln
-132,04 mln
Foizlarni toʻlash boʻyicha sof xarajatlar
-89,00 mln
13,71 mln
-105,71 mln
172,99 mln
Amortizatsiya ajratmalari
-
-
5,78 mlrd
-
EBITDA
3,88 mlrd
6,81 mlrd
5,65 mlrd
4,24 mlrd
Aktivlarni sotishdan olingan foyda yoki zarar
-
-
-
-
AI kontentda xatolar boʻlishi mumkin. Batafsil
Google ilovalari